ArticleFrontiers in oncology2022
Risk prediction of pancreatic cancer using AI analysis of pancreatic subregions in computed tomography images.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Diagnostic Performance of Artificial Intelligence in Detecting and Distinguishing Pancreatic Ductal Adenocarcinoma via Computed Tomography: A Systematic Review and Meta-Analysis.Journal of imaging informatics in medicine · 2026Pooled it
- Deep learning models for pancreatic cancer detection on CT: a meta-analysis.Frontiers in medicine · 2026Pooled it
- Accuracy of machine learning models for pre-diagnosis and diagnosis of pancreatic ductal adenocarcinoma in contrast-CT images: a systematic review and meta-analysis.Abdominal radiology (New York) · 2025Pooled it
- From Bench to Bedside: The Path Toward Real-World Translation for Artificial Intelligence in Pancreatic Cancer Detection.Korean journal of radiology · 2026Review
- Article
- Predictive imaging in abdominal oncology: current trends and future directions.Japanese journal of radiology · 2026Review
- Landmark-Based Pancreas Sub-region Segmentation in CT.Journal of imaging informatics in medicine · 2026Article
- Beyond sensitivity and specificity: Redefining the era connotation of "low-risk" in pancreatic cancer screening.World journal of clinical oncology · 2026Article
- Clinical Application Progress of Artificial Intelligence in Pancreatic Cancer: From Diagnosis to Immunotherapy.Oncology research · 2026Review
- Detection and Classification of Pancreatic Cancer Nodules on CT Images using U-Net and Ensemble Models.Current medical imaging · 2026Article
- Clinical Applications of Quantitative Imaging and Artificial Intelligence for Pancreatic Cance.Seminars in radiation oncology · 2025Review
- Early detection of pancreatic cancer on computed tomography: advancements with deep learning.Radiology advances · 2025Review
- Advancements in Radiomics-Based AI for Pancreatic Ductal Adenocarcinoma.Bioengineering (Basel, Switzerland) · 2025Review
- Review
- AI-Driven insights in pancreatic cancer imaging: from pre-diagnostic detection to prognostication.Abdominal radiology (New York) · 2025Review
- Article
- Pancreas segmentation using AI developed on the largest CT dataset with multi-institutional validation and implications for early cancer detection.Scientific reports · 2025Article
- Review
- Habitat radiomics based on CT images to predict survival and immune status in hepatocellular carcinoma, a multi-cohort validation study.Translational oncology · 2025Article
- Early detection of pancreatic cancer in the era of precision medicine.Abdominal radiology (New York) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early detection of Pancreatic Ductal Adenocarcinoma (PDAC) is complicated as PDAC remains asymptomatic until cancer advances to late stages when treatment is mostly ineffective. Stratifying the risk of developing PDAC can improve early detection as subsequent screening of high-risk individuals through specialized surveillance systems reduces the chance of misdiagnosis at the initial stage of cancer. Risk stratification is however challenging as PDAC lacks specific predictive biomarkers. Studies reported that the pancreas undergoes local morphological changes in response to underlying biological evolution associated with PDAC development. Accurate identification of these changes can help stratify the risk of PDAC. In this retrospective study, an extensive radiomic analysis of the precancerous pancreatic subregions was performed using abdominal Computed Tomography (CT) scans. The analysis was performed using 324 pancreatic subregions identified in 108 contrast-enhanced abdominal CT scans with equal proportion from healthy control, pre-diagnostic, and diagnostic groups. In a pairwise feature analysis, several textural features were found potentially predictive of PDAC. A machine learning classifier was then trained to perform risk prediction of PDAC by automatically classifying the CT scans into healthy control (low-risk) and pre-diagnostic (high-risk) classes and specifying the subregion(s) likely to develop a tumor. The proposed model was trained on CT scans from multiple phases. Whereas using 42 CT scans from the venous phase, model validation was performed which resulted in ~89.3% classification accuracy on average, with sensitivity and specificity reaching 86% and 93%, respectively, for predicting the development of PDAC (i.e., high-risk). To our knowledge, this is the first model that unveiled microlevel precancerous changes across pancreatic subregions and quantified the risk of developing PDAC. The model demonstrated improved prediction by 3.3% in comparison to the state-of-the-art method that considers the global (whole pancreas) features for PDAC prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.